BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumar VV, Chandrasekar D, Ramakrishna S, Kishan V, Rao YM, Diwan PV. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm. 2007;335:167-175. [PMID: 17161566 DOI: 10.1016/j.ijpharm.2006.11.004] [Cited by in Crossref: 123] [Cited by in F6Publishing: 115] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Ganesan P, Narayanasamy D. Lipid nanoparticles: Different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustainable Chemistry and Pharmacy 2017;6:37-56. [DOI: 10.1016/j.scp.2017.07.002] [Cited by in Crossref: 121] [Cited by in F6Publishing: 44] [Article Influence: 24.2] [Reference Citation Analysis]
2 Gorajana A, Rajendran A, Dua K, Pabreja K, Hoon TP. Preparation, Characterization, and In Vitro Evaluation of Nitrendipine Solid Dispersions. Journal of Dispersion Science and Technology 2012;33:676-84. [DOI: 10.1080/01932691.2011.579829] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
3 Pokharkar VB, Mendiratta C, Kyadarkunte AY, Bhosale SH, Barhate GA. Skin delivery aspects of benzoyl peroxide-loaded solid lipid nanoparticles for acne treatment. Therapeutic Delivery 2014;5:635-52. [DOI: 10.4155/tde.14.31] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
4 Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release. 2009;133:238-244. [PMID: 18951932 DOI: 10.1016/j.jconrel.2008.10.002] [Cited by in Crossref: 399] [Cited by in F6Publishing: 352] [Article Influence: 28.5] [Reference Citation Analysis]
5 Shilpi D, Kushwah V, Agrawal AK, Jain S. Improved Stability and Enhanced Oral Bioavailability of Atorvastatin Loaded Stearic Acid Modified Gelatin Nanoparticles. Pharm Res 2017;34:1505-16. [DOI: 10.1007/s11095-017-2173-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
6 Castro SR, Ribeiro LNM, Breitkreitz MC, Guilherme VA, Rodrigues da Silva GH, Mitsutake H, Alcântara ACS, Yokaichiya F, Franco MKKD, Clemens D, Kent B, Lancellotti M, de Araújo DR, de Paula E. A pre-formulation study of tetracaine loaded in optimized nanostructured lipid carriers. Sci Rep 2021;11:21463. [PMID: 34728779 DOI: 10.1038/s41598-021-99743-6] [Reference Citation Analysis]
7 He Y, Zhan C, Pi C, Zuo Y, Yang S, Hu M, Bai Y, Zhao L, Wei Y. Enhanced Oral Bioavailability of Felodipine from Solid Lipid Nanoparticles Prepared Through Effervescent Dispersion Technique. AAPS PharmSciTech 2020;21:170. [PMID: 32529303 DOI: 10.1208/s12249-020-01711-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Rouco H, Diaz-rodriguez P, Remuñán-lópez C, Landin M. Recent advances in solid lipid nanoparticles formulation and clinical applications. Nanomaterials for Clinical Applications. Elsevier; 2020. pp. 213-47. [DOI: 10.1016/b978-0-12-816705-2.00007-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Kushwaha AK, Vuddanda PR, Karunanidhi P, Singh SK, Singh S. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability. Biomed Res Int 2013;2013:584549. [PMID: 24228255 DOI: 10.1155/2013/584549] [Cited by in Crossref: 77] [Cited by in F6Publishing: 57] [Article Influence: 8.6] [Reference Citation Analysis]
10 Rawat MK, Jain A, Singh S. Studies on Binary Lipid Matrix Based Solid Lipid Nanoparticles of Repaglinide: in Vitro and in Vivo Evaluation. Journal of Pharmaceutical Sciences 2011;100:2366-78. [DOI: 10.1002/jps.22435] [Cited by in Crossref: 58] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
11 Parashar D, Rajendran V, Shukla R, Sistla R. Lipid-based nanocarriers for delivery of small interfering RNA for therapeutic use. European Journal of Pharmaceutical Sciences 2020;142:105159. [DOI: 10.1016/j.ejps.2019.105159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
12 Wang H, Li L, Ye J, Wang R, Wang R, Hu J, Wang Y, Dong W, Xia X, Yang Y, Gao Y, Gao L, Liu Y. Improving the Oral Bioavailability of an Anti-Glioma Prodrug CAT3 Using Novel Solid Lipid Nanoparticles Containing Oleic Acid-CAT3 Conjugates. Pharmaceutics 2020;12:E126. [PMID: 32028734 DOI: 10.3390/pharmaceutics12020126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
13 Golmohammadzadeh S, Mokhtari M, Jaafari MR. Preparation, characterization and evaluation of moisturizing and UV protecting effects of topical solid lipid nanoparticles. Braz J Pharm Sci 2012;48:683-90. [DOI: 10.1590/s1984-82502012000400012] [Cited by in Crossref: 17] [Article Influence: 1.7] [Reference Citation Analysis]
14 Patil GB, Surana SJ. Fabrication and statistical optimization of surface engineered PLGA nanoparticles for naso-brain delivery of ropinirole hydrochloride: in-vitro-ex-vivo studies. J Biomater Sci Polym Ed 2013;24:1740-56. [PMID: 23705812 DOI: 10.1080/09205063.2013.798880] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
15 Venishetty VK, Chede R, Komuravelli R, Adepu L, Sistla R, Diwan PV. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: A novel strategy to avoid intraduodenal administration. Colloids and Surfaces B: Biointerfaces 2012;95:1-9. [DOI: 10.1016/j.colsurfb.2012.01.001] [Cited by in Crossref: 96] [Cited by in F6Publishing: 86] [Article Influence: 9.6] [Reference Citation Analysis]
16 Li X, Qu B, Jin X, Hai L, Wu Y. Design, synthesis and biological evaluation for docetaxel-loaded brain targeting liposome with “lock-in” function. Journal of Drug Targeting 2013;22:251-61. [DOI: 10.3109/1061186x.2013.865032] [Cited by in Crossref: 12] [Article Influence: 1.3] [Reference Citation Analysis]
17 Meng K, Chen D, Yang F, Zhang A, Tao Y, Qu W, Pan Y, Hao H, Xie S. Intracellular delivery, accumulation, and discrepancy in antibacterial activity of four enrofloxacin-loaded fatty acid solid lipid nanoparticles. Colloids Surf B Biointerfaces 2020;194:111196. [PMID: 32599504 DOI: 10.1016/j.colsurfb.2020.111196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kawish S, Ahmed S, Gull A, Aslam M, Pandit J, Aqil M, Sultana Y. Development of nabumetone loaded lipid nano-scaffold for the effective oral delivery; optimization, characterization, drug release and pharmacodynamic study. Journal of Molecular Liquids 2017;231:514-22. [DOI: 10.1016/j.molliq.2017.01.107] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
19 García-gonzález C, Sousa ASD, Argemí A, Periago AL, Saurina J, Duarte C, Domingo C. Production of hybrid lipid-based particles loaded with inorganic nanoparticles and active compounds for prolonged topical release. International Journal of Pharmaceutics 2009;382:296-304. [DOI: 10.1016/j.ijpharm.2009.08.033] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
20 Venishetty VK, Samala R, Komuravelli R, Kuncha M, Sistla R, Diwan PV. β-Hydroxybutyric acid grafted solid lipid nanoparticles: A novel strategy to improve drug delivery to brain. Nanomedicine: Nanotechnology, Biology and Medicine 2013;9:388-97. [DOI: 10.1016/j.nano.2012.08.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
21 Joseph E, Saha RN. Investigations on pharmacokinetics and biodistribution of polymeric and solid lipid nanoparticulate systems of atypical antipsychotic drug: effect of material used and surface modification. Drug Development and Industrial Pharmacy 2017;43:678-86. [DOI: 10.1080/03639045.2016.1278014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
22 Makwana V, Jain R, Patel K, Nivsarkar M, Joshi A. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach. International Journal of Pharmaceutics 2015;495:439-46. [DOI: 10.1016/j.ijpharm.2015.09.014] [Cited by in Crossref: 89] [Cited by in F6Publishing: 72] [Article Influence: 12.7] [Reference Citation Analysis]
23 Kumar V, Kharb R, Chaudhary H. Optimization & design of isradipine loaded solid lipid nanobioparticles using rutin by Taguchi methodology. International Journal of Biological Macromolecules 2016;92:338-46. [DOI: 10.1016/j.ijbiomac.2016.07.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
24 Severino P, Santana MHA, Souto EB. Optimizing SLN and NLC by 22 full factorial design: Effect of homogenization technique. Materials Science and Engineering: C 2012;32:1375-9. [DOI: 10.1016/j.msec.2012.04.017] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
25 Souto EB, Doktorovová S. Chapter 6 - Solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery. Methods Enzymol 2009;464:105-29. [PMID: 19903552 DOI: 10.1016/S0076-6879(09)64006-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
26 Gao X, Zhang X, Zhang X, Wang Y, Sun L, Li C. Amphiphilic polylactic acid-hyperbranched polyglycerol nanoparticles as a controlled release system for poorly water-soluble drugs: physicochemical characterization. Journal of Pharmacy and Pharmacology 2011;63:757-64. [DOI: 10.1111/j.2042-7158.2011.01260.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
27 Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011;12:62-76. [PMID: 21174180 DOI: 10.1208/s12249-010-9563-0] [Cited by in Crossref: 390] [Cited by in F6Publishing: 314] [Article Influence: 32.5] [Reference Citation Analysis]
28 Elnaggar YS, El-Massik MA, Abdallah OY. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles. Int J Nanomedicine 2011;6:3195-205. [PMID: 22238508 DOI: 10.2147/IJN.S25825] [Cited by in Crossref: 53] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
29 Jensen LB, Magnussson E, Gunnarsson L, Vermehren C, Nielsen HM, Petersson K. Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles. International Journal of Pharmaceutics 2010;390:53-60. [DOI: 10.1016/j.ijpharm.2009.10.022] [Cited by in Crossref: 62] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
30 Nafee N, Gaber DM, Elzoghby AO, Helmy MW, Abdallah OY. Promoted Antitumor Activity of Myricetin against Lung Carcinoma Via Nanoencapsulated Phospholipid Complex in Respirable Microparticles. Pharm Res 2020;37:82. [PMID: 32291520 DOI: 10.1007/s11095-020-02794-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Tran TH, Ramasamy T, Truong DH, Choi HG, Yong CS, Kim JO. Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. AAPS PharmSciTech 2014;15:1509-15. [PMID: 25035071 DOI: 10.1208/s12249-014-0175-y] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 9.5] [Reference Citation Analysis]
32 Aboud HM, El Komy MH, Ali AA, El Menshawe SF, Abd Elbary A. Development, Optimization, and Evaluation of Carvedilol-Loaded Solid Lipid Nanoparticles for Intranasal Drug Delivery. AAPS PharmSciTech 2016;17:1353-65. [PMID: 26743643 DOI: 10.1208/s12249-015-0440-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
33 Varshosaz J, Eskandari S, Tabakhian M. Production and optimization of valproic acid nanostructured lipid carriers by the Taguchi design. Pharmaceutical Development and Technology 2010;15:89-96. [DOI: 10.3109/10837450903013568] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
34 Souto E, Doktorovova S, Boonme P. Lipid-based colloidal systems (nanoparticles, microemulsions) for drug delivery to the skin: materials and end-product formulations. Journal of Drug Delivery Science and Technology 2011;21:43-54. [DOI: 10.1016/s1773-2247(11)50005-x] [Cited by in Crossref: 31] [Article Influence: 2.8] [Reference Citation Analysis]
35 Singh RP, Gangadharappa H, Mruthunjaya K. Phospholipids: Unique carriers for drug delivery systems. Journal of Drug Delivery Science and Technology 2017;39:166-79. [DOI: 10.1016/j.jddst.2017.03.027] [Cited by in Crossref: 51] [Cited by in F6Publishing: 29] [Article Influence: 10.2] [Reference Citation Analysis]
36 Anwar W, Dawaba HM, Afouna MI, Samy AM, Rashed MH, Abdelaziz AE. Enhancing the Oral Bioavailability of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers: In Vitro Characterization and Absorption in Rats after Oral Administration. Pharmaceutics 2020;12:E1047. [PMID: 33142816 DOI: 10.3390/pharmaceutics12111047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Zhang Z, Lu Y, Qi J, Wu W. An update on oral drug delivery via intestinal lymphatic transport. Acta Pharm Sin B 2021;11:2449-68. [PMID: 34522594 DOI: 10.1016/j.apsb.2020.12.022] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Patil GB, Patil ND, Deshmukh PK, Patil PO, Bari SB. Nanostructured lipid carriers as a potential vehicle for Carvedilol delivery: Application of factorial design approach. Artificial Cells, Nanomedicine, and Biotechnology 2014;44:12-9. [DOI: 10.3109/21691401.2014.909820] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
39 Guo M, Dong Y, Wang Y, Ma M, He Z, Fu Q. Fabrication, characterization, stability and in vitro evaluation of nitrendipine nanocrystals by media milling. Powder Technology 2019;358:20-8. [DOI: 10.1016/j.powtec.2018.08.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
40 Kumar Gaur P, Mishra S, Purohit S. Nanovesicles of nitrendipine with lipid complex for transdermal delivery: pharmacokinetic and pharmacodynamic studies. Artif Cells Nanomed Biotechnol 2016;44:1684-93. [PMID: 26375758 DOI: 10.3109/21691401.2015.1080170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Nasiri F, Faghfouri L, Hamidi M. Preparation, optimization, and in-vitro characterization of α-tocopherol-loaded solid lipid nanoparticles (SLNs). Drug Dev Ind Pharm 2020;46:159-71. [PMID: 31894713 DOI: 10.1080/03639045.2019.1711388] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
42 Patil GB, Surana SJ. Bio-fabrication and statistical optimization of polysorbate 80 coated chitosan nanoparticles of tapentadol hydrochloride for central antinociceptive effect: in vitroin vivo studies. Artificial Cells, Nanomedicine, and Biotechnology 2017;45:505-14. [DOI: 10.3109/21691401.2016.1163713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
43 Shirodkar RK, Kumar L, Mutalik S, Lewis S. Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Emerging Lipid Based Drug Delivery Systems. Pharm Chem J 2019;53:440-53. [DOI: 10.1007/s11094-019-02017-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
44 Kaithwas V, Dora CP, Kushwah V, Jain S. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability. Colloids and Surfaces B: Biointerfaces 2017;154:10-20. [DOI: 10.1016/j.colsurfb.2017.03.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
45 Hammad RW, Sanad RAB, Abdelmalk NS, Aziz RL, Torad FA. Intranasal Surface-Modified Mosapride Citrate-Loaded Nanostructured Lipid Carriers (MOS-SMNLCs) for Treatment of Reflux Diseases: In vitro Optimization, Pharmacodynamics, and Pharmacokinetic Studies. AAPS PharmSciTech 2018;19:3791-808. [PMID: 30280358 DOI: 10.1208/s12249-018-1142-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 de Almeida AE, Souza ALR, Cassimiro DL, Gremião MPD, Ribeiro CA, Crespi MS. Thermal characterization of solid lipid nanoparticles containing praziquantel. J Therm Anal Calorim 2012;108:333-9. [DOI: 10.1007/s10973-011-1814-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
47 Varshosaz J, Tabbakhian M, Mohammadi MY. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res 2010;20:286-96. [PMID: 19958118 DOI: 10.3109/08982100903443065] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 4.1] [Reference Citation Analysis]
48 Morsi NM, Ghorab DM, Badie HA. Brain targeted solid lipid nanoparticles for brain ischemia: preparation and in vitro characterization. Pharm Dev Technol 2013;18:736-44. [PMID: 23477526 DOI: 10.3109/10837450.2012.734513] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
49 Kola Srinivas NS, Verma R, Pai Kulyadi G, Kumar L. A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization. Int J Nanomedicine 2017;12:15-28. [PMID: 28031710 DOI: 10.2147/IJN.S122729] [Cited by in Crossref: 40] [Cited by in F6Publishing: 5] [Article Influence: 6.7] [Reference Citation Analysis]
50 Kumar R. Lipid-Based Nanoparticles for Drug-Delivery Systems. Nanocarriers for Drug Delivery. Elsevier; 2019. pp. 249-84. [DOI: 10.1016/b978-0-12-814033-8.00008-4] [Cited by in Crossref: 22] [Article Influence: 7.3] [Reference Citation Analysis]
51 B A, D N, Veerabrahma K. Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation. Artif Cells Nanomed Biotechnol 2018;46:126-37. [PMID: 28290712 DOI: 10.1080/21691401.2017.1299160] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
52 Ahadian S, Finbloom JA, Mofidfar M, Diltemiz SE, Nasrollahi F, Davoodi E, Hosseini V, Mylonaki I, Sangabathuni S, Montazerian H, Fetah K, Nasiri R, Dokmeci MR, Stevens MM, Desai TA, Khademhosseini A. Micro and nanoscale technologies in oral drug delivery. Adv Drug Deliv Rev 2020;157:37-62. [PMID: 32707147 DOI: 10.1016/j.addr.2020.07.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
53 Jensen L, Petersson K, Nielsen H. In vitro penetration properties of solid lipid nanoparticles in intact and barrier-impaired skin. European Journal of Pharmaceutics and Biopharmaceutics 2011;79:68-75. [DOI: 10.1016/j.ejpb.2011.05.012] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 6.4] [Reference Citation Analysis]
54 Elbrink K, Van Hees S, Chamanza R, Roelant D, Loomans T, Holm R, Kiekens F. Application of solid lipid nanoparticles as a long-term drug delivery platform for intramuscular and subcutaneous administration: In vitro and in vivo evaluation. Eur J Pharm Biopharm 2021;163:158-70. [PMID: 33848628 DOI: 10.1016/j.ejpb.2021.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Martín Giménez VM, Kassuha DE, Manucha W. Nanomedicine applied to cardiovascular diseases: latest developments. Ther Adv Cardiovasc Dis 2017;11:133-42. [PMID: 28198204 DOI: 10.1177/1753944717692293] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 7.2] [Reference Citation Analysis]
56 Voruganti S, Rapolu K, Tota S, Yamsani SK, Yamsani MR. Effect of pomegranate juice on the pharmacokinetics of nitrendipine in rabbits. Eur J Drug Metab Pharmacokinet 2012;37:77-81. [DOI: 10.1007/s13318-011-0075-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
57 Baek JS, Cho CW. A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells. Oncotarget 2017;8:30369-82. [PMID: 28423731 DOI: 10.18632/oncotarget.16153] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 11.5] [Reference Citation Analysis]
58 Ahmad N, Banala VT, Kushwaha P, Karvande A, Sharma S, Tripathi AK, Verma A, Trivedi R, Mishra PR. Quercetin-loaded solid lipid nanoparticles improve osteoprotective activity in an ovariectomized rat model: a preventive strategy for post-menopausal osteoporosis. RSC Adv 2016;6:97613-28. [DOI: 10.1039/c6ra17141a] [Cited by in Crossref: 17] [Article Influence: 2.8] [Reference Citation Analysis]
59 Gupta P, Garcia E, Sarkar A, Kapoor S, Rafiq K, Chand HS, Jayant RD. Nanoparticle Based Treatment for Cardiovascular Diseases. CHDDT 2019;19:33-44. [DOI: 10.2174/1871529x18666180508113253] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 5.3] [Reference Citation Analysis]
60 Singh A, Ahmad I, Akhter S, Jain GK, Iqbal Z, Talegaonkar S, Ahmad FJ. Nanocarrier based formulation of Thymoquinone improves oral delivery: Stability assessment, in vitro and in vivo studies. Colloids and Surfaces B: Biointerfaces 2013;102:822-32. [DOI: 10.1016/j.colsurfb.2012.08.038] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 7.6] [Reference Citation Analysis]
61 Patel K, Padhye S, Nagarsenker M. Duloxetine HCl lipid nanoparticles: preparation, characterization, and dosage form design. AAPS PharmSciTech 2012;13:125-33. [PMID: 22167415 DOI: 10.1208/s12249-011-9727-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
62 Yang T, Sheng HH, Feng NP, Wei H, Wang ZT, Wang CH. Preparation of andrographolide-loaded solid lipid nanoparticles and their in vitro and in vivo evaluations: characteristics, release, absorption, transports, pharmacokinetics, and antihyperlipidemic activity. J Pharm Sci 2013;102:4414-25. [PMID: 24166599 DOI: 10.1002/jps.23758] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
63 Khalil RM, Abd-Elbary A, Kassem MA, Ghorab MM, Basha M. Nanostructured lipid carriers (NLCs) versus solid lipid nanoparticles (SLNs) for topical delivery of meloxicam. Pharm Dev Technol 2014;19:304-14. [PMID: 23528038 DOI: 10.3109/10837450.2013.778872] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
64 Wang L, Li H, Wang S, Liu R, Wu Z, Wang C, Wang Y, Chen M. Enhancing the antitumor activity of berberine hydrochloride by solid lipid nanoparticle encapsulation. AAPS PharmSciTech 2014;15:834-44. [PMID: 24696391 DOI: 10.1208/s12249-014-0112-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
65 Rotta J, Pham PD, Lapinte V, Borsali R, Minatti E, Robin J. Synthesis of Amphiphilic Polymers Based on Fatty Acids and Glycerol-Derived Monomers - A Study of Their Self-Assembly in Water. Macromol Chem Phys 2014;215:131-9. [DOI: 10.1002/macp.201300483] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
66 Ahad A, Shakeel F, Raish M, Al-jenoobi FI, Al-mohizea AM. Solubility and Thermodynamic Analysis of Antihypertensive Agent Nitrendipine in Different Pure Solvents at the Temperature Range of 298.15 to 318.15°K. AAPS PharmSciTech 2017;18:2737-43. [DOI: 10.1208/s12249-017-0759-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
67 Voruganti S, Yamsani SK, Ravula SK, Gannu R, Yamsani MR. Effect of Pomegranate Juice on Intestinal Transport and Pharmacokinetics of Nitrendipine in Rats: PHARMACOKINETIC INTERACTION BETWEEN POMEGRANATE JUICE AND NITRENDIPINE. Phytother Res 2012;26:1240-5. [DOI: 10.1002/ptr.3704] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
68 Dudhipala N, Veerabrahma K. Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: Pharmacokinetic and pharmacodynamic evaluation. European Journal of Pharmaceutics and Biopharmaceutics 2017;110:47-57. [DOI: 10.1016/j.ejpb.2016.10.022] [Cited by in Crossref: 46] [Cited by in F6Publishing: 29] [Article Influence: 9.2] [Reference Citation Analysis]
69 Buse J, El-aneed A. Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances. Nanomedicine 2010;5:1237-60. [DOI: 10.2217/nnm.10.107] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]
70 Büyükköroğlu G, Şenel B, Gezgin S, Dinh T. The simultaneous delivery of paclitaxel and Herceptin® using solid lipid nanoparticles: In vitro evaluation. Journal of Drug Delivery Science and Technology 2016;35:98-105. [DOI: 10.1016/j.jddst.2016.06.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
71 Burra M, Jukanti R, Janga KY, Sunkavalli S, Velpula A, Ampati S, Jayaveera K. Enhanced intestinal absorption and bioavailability of raloxifene hydrochloride via lyophilized solid lipid nanoparticles. Advanced Powder Technology 2013;24:393-402. [DOI: 10.1016/j.apt.2012.09.002] [Cited by in Crossref: 40] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
72 Suram D, Narala A, Veerabrahma K. Development, characterization, comparative pharmacokinetic and pharmacodynamic studies of iloperidone solid SMEDDS and liquisolid compact. Drug Development and Industrial Pharmacy 2020;46:587-96. [DOI: 10.1080/03639045.2020.1742142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
73 Wu T, Zheng WL, Zhang SZ, Sun JH, Yuan H. Bimodal visualization of colorectal uptake of nanoparticles in dimethylhydrazine-treated mice. World J Gastroenterol 2011; 17(31): 3614-3622 [PMID: 21987608 DOI: 10.3748/wjg.v17.i31.3614] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
74 Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Delivery 2014;23:395-404. [DOI: 10.3109/10717544.2014.914986] [Cited by in Crossref: 65] [Cited by in F6Publishing: 44] [Article Influence: 8.1] [Reference Citation Analysis]
75 Baek J, Shin S, Cho C. Effect of lipid on physicochemical properties of solid lipid nanoparticle of paclitaxel. Journal of Pharmaceutical Investigation 2012;42:279-83. [DOI: 10.1007/s40005-012-0038-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
76 Lee P, Zhang R, Li V, Liu X, Sun RW, Che CM, Wong KK. Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation. Int J Nanomedicine 2012;7:731-7. [PMID: 22359452 DOI: 10.2147/IJN.S28783] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
77 Daneshmand S, Golmohammadzadeh S, Jaafari MR, Movaffagh J, Rezaee M, Sahebkar A, Malaekeh-Nikouei B. Encapsulation challenges, the substantial issue in solid lipid nanoparticles characterization. J Cell Biochem 2018;119:4251-64. [PMID: 29243841 DOI: 10.1002/jcb.26617] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
78 Siddiqui A, Alayoubi A, Nazzal S. The effect of emulsifying wax on the physical properties of CTAB-based solid lipid nanoparticles (SLN). Pharmaceutical Development and Technology 2012;19:125-8. [DOI: 10.3109/10837450.2012.751401] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
79 Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J. Nanocarriers as treatment modalities for hypertension. Drug Deliv 2017;24:358-69. [PMID: 28165823 DOI: 10.1080/10717544.2016.1255999] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
80 Maddiboyina B, Jhawat V, Nakkala RK, Desu PK, Gandhi S. Design expert assisted formulation, characterization and optimization of microemulsion based solid lipid nanoparticles of repaglinide. Prog Biomater 2021;10:309-20. [PMID: 34813041 DOI: 10.1007/s40204-021-00174-3] [Reference Citation Analysis]
81 Patil A, Tuencar V, Gadad A, Dandagi P, Masareddy R. Nanostructured lipid carrier-incorporated gel for efficient topical delivery of fluconazole. Ther Deliv 2021;12:565-74. [PMID: 34187177 DOI: 10.4155/tde-2021-0029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Rao S, Tan A, Thomas N, Prestidge CA. Perspective and potential of oral lipid-based delivery to optimize pharmacological therapies against cardiovascular diseases. J Control Release 2014;193:174-87. [PMID: 24852093 DOI: 10.1016/j.jconrel.2014.05.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
83 Venishetty VK, Komuravelli R, Kuncha M, Sistla R, Diwan PV. Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. Nanomedicine: Nanotechnology, Biology and Medicine 2013;9:111-21. [DOI: 10.1016/j.nano.2012.03.003] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 6.8] [Reference Citation Analysis]
84 Khezri K, Saeedi M, Morteza-semnani K, Akbari J, Rostamkalaei SS. An emerging technology in lipid research for targeting hydrophilic drugs to the skin in the treatment of hyperpigmentation disorders: kojic acid-solid lipid nanoparticles. Artificial Cells, Nanomedicine, and Biotechnology 2020;48:841-53. [DOI: 10.1080/21691401.2020.1770271] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
85 Baek J, Cho C. Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles. International Journal of Pharmaceutics 2015;478:617-24. [DOI: 10.1016/j.ijpharm.2014.12.018] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 8.6] [Reference Citation Analysis]
86 Youssef T, Fadel M, Fahmy R, Kassab K. Evaluation of hypericin-loaded solid lipid nanoparticles: Physicochemical properties, photostability and phototoxicity. Pharmaceutical Development and Technology 2012;17:177-86. [DOI: 10.3109/10837450.2010.529148] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
87 Roger E, Lagarce F, Garcion E, Benoit JP. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond) 2010;5:287-306. [PMID: 20148639 DOI: 10.2217/nnm.09.110] [Cited by in Crossref: 206] [Cited by in F6Publishing: 184] [Article Influence: 17.2] [Reference Citation Analysis]
88 Meenambal R, Srinivas Bharath MM. Nanocarriers for effective nutraceutical delivery to the brain. Neurochem Int 2020;140:104851. [PMID: 32976906 DOI: 10.1016/j.neuint.2020.104851] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
89 Rawat MK, Jain A, Mishra A, Muthu MS, Singh S. Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery. Therapeutic Delivery 2010;1:63-73. [DOI: 10.4155/tde.10.7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
90 Katla VM, Veerabrahma K. Cationic solid self micro emulsifying drug delivery system (SSMED) of losartan: Formulation development, characterization and in vivo evaluation. Journal of Drug Delivery Science and Technology 2016;35:190-9. [DOI: 10.1016/j.jddst.2016.04.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
91 Smith A, Giunta B, Bickford PC, Fountain M, Tan J, Shytle RD. Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer’s disease. Int J Pharm. 2010;389:207-212. [PMID: 20083179 DOI: 10.1016/j.ijpharm.2010.01.012] [Cited by in Crossref: 158] [Cited by in F6Publishing: 138] [Article Influence: 13.2] [Reference Citation Analysis]
92 Poovi G, Damodharan N. Lipid nanoparticles: A challenging approach for oral delivery of BCS Class-II drugs. Future Journal of Pharmaceutical Sciences 2018;4:191-205. [DOI: 10.1016/j.fjps.2018.04.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 9.3] [Reference Citation Analysis]
93 Tan SLJ, Billa N. Improved Bioavailability of Poorly Soluble Drugs through Gastrointestinal Muco-Adhesion of Lipid Nanoparticles. Pharmaceutics 2021;13:1817. [PMID: 34834232 DOI: 10.3390/pharmaceutics13111817] [Reference Citation Analysis]
94 Piazzini V, Micheli L, Luceri C, D'Ambrosio M, Cinci L, Ghelardini C, Bilia AR, Di Cesare Mannelli L, Bergonzi MC. Nanostructured lipid carriers for oral delivery of silymarin: Improving its absorption and in vivo efficacy in type 2 diabetes and metabolic syndrome model. Int J Pharm 2019;572:118838. [PMID: 31715362 DOI: 10.1016/j.ijpharm.2019.118838] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
95 Yassemi A, Kashanian S, Zhaleh H. Folic acid receptor-targeted solid lipid nanoparticles to enhance cytotoxicity of letrozole through induction of caspase-3 dependent-apoptosis for breast cancer treatment. Pharmaceutical Development and Technology 2020;25:397-407. [DOI: 10.1080/10837450.2019.1703739] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
96 Alam M, Ahmed S, N, Moon G, Aqil M, Sultana Y. Chemical engineering of a lipid nano-scaffold for the solubility enhancement of an antihyperlipidaemic drug, simvastatin; preparation, optimization, physicochemical characterization and pharmacodynamic study. Artificial Cells, Nanomedicine, and Biotechnology 2017. [DOI: 10.1080/21691401.2017.1396223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
97 Elkomy MH, El Menshawe SF, Eid HM, Ali AM. Development of a nanogel formulation for transdermal delivery of tenoxicam: a pharmacokinetic-pharmacodynamic modeling approach for quantitative prediction of skin absorption. Drug Dev Ind Pharm 2017;43:531-44. [PMID: 27910712 DOI: 10.1080/03639045.2016.1268153] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
98 Quan J, Kim S, Pan C, Chung D. Characterization of fucoxanthin-loaded microspheres composed of cetyl palmitate-based solid lipid core and fish gelatin–gum arabic coacervate shell. Food Research International 2013;50:31-7. [DOI: 10.1016/j.foodres.2012.09.040] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
99 Baek J, Cho C. Comparison of solid lipid nanoparticles for encapsulating paclitaxel or docetaxel. Journal of Pharmaceutical Investigation 2015;45:625-31. [DOI: 10.1007/s40005-015-0182-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
100 Xie S, Zhu L, Dong Z, Wang X, Wang Y, Li X, Zhou W. Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: Influences of fatty acids. Colloids and Surfaces B: Biointerfaces 2011;83:382-7. [DOI: 10.1016/j.colsurfb.2010.12.014] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
101 Hesari M, Mohammadi P, Khademi F, Shackebaei D, Momtaz S, Moasefi N, Farzaei MH, Abdollahi M. Current Advances in the Use of Nanophytomedicine Therapies for Human Cardiovascular Diseases. Int J Nanomedicine 2021;16:3293-315. [PMID: 34007178 DOI: 10.2147/IJN.S295508] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
102 Kumar V, Chaudhary H, Kamboj A. Development and evaluation of isradipine via rutin-loaded coated solid-lipid nanoparticles. Interv Med Appl Sci 2018;10:236-46. [PMID: 30792921 DOI: 10.1556/1646.10.2018.45] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
103 Varshosaz J, Minayian M, Moazen E. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. Journal of Liposome Research 2010;20:115-23. [DOI: 10.3109/08982100903161456] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
104 Li R, Lim S, Choi H, Lee M. Solid Lipid Nanoparticles as Drug Delivery System for Water-Insoluble Drugs. Journal of Pharmaceutical Investigation 2010;40:63-73. [DOI: 10.4333/kps.2010.40.s.063] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
105 Jones E, Ojewole E, Kalhapure R, Govender T. In vitro comparative evaluation of monolayered multipolymeric films embedded with didanosine-loaded solid lipid nanoparticles: a potential buccal drug delivery system for ARV therapy. Drug Development and Industrial Pharmacy 2014;40:669-79. [DOI: 10.3109/03639045.2014.892957] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
106 Khursheed R, Singh SK, Wadhwa S, Gulati M, Awasthi A, Kumar R, Ramanunny AK, Kapoor B, Kumar P, Corrie L. Exploring role of probiotics and Ganoderma lucidum extract powder as solid carriers to solidify liquid self-nanoemulsifying delivery systems loaded with curcumin. Carbohydrate Polymers 2020;250:116996. [DOI: 10.1016/j.carbpol.2020.116996] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
107 Ye J, Liu AL. Chapter 6 Functionalization of Carbon Nanotubes and Nanoparticles with Lipid. Elsevier; 2008. pp. 201-24. [DOI: 10.1016/s1554-4516(08)00206-8] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
108 Singh I, Swami R, Pooja D, Jeengar MK, Khan W, Sistla R. Lactoferrin bioconjugated solid lipid nanoparticles: a new drug delivery system for potential brain targeting. Journal of Drug Targeting 2016;24:212-23. [DOI: 10.3109/1061186x.2015.1068320] [Cited by in Crossref: 60] [Cited by in F6Publishing: 13] [Article Influence: 8.6] [Reference Citation Analysis]
109 Graves RA, Ledet GA, Nation CA, Pramar YV, Bostanian LA, Mandal TK. Effect of squalane on mebendazole-loaded Compritol® nanoparticles. J Biomater Sci Polym Ed 2015;26:868-80. [PMID: 26062393 DOI: 10.1080/09205063.2015.1061351] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
110 Sanjula B, Shah FM, Javed A, Alka A. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J Drug Target 2009;17:249-56. [PMID: 19255893 DOI: 10.1080/10611860902718672] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 5.9] [Reference Citation Analysis]
111 Sarhadi S, Gholizadeh M, Moghadasian T, Golmohammadzadeh S. Moisturizing effects of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) using deionized and magnetized water by in vivo and in vitro methods. Iran J Basic Med Sci 2020;23:337-43. [PMID: 32440320 DOI: 10.22038/IJBMS.2020.39587.9397] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
112 Motawea A, Borg T, Abd El-Gawad AEH. Topical phenytoin nanostructured lipid carriers: design and development. Drug Dev Ind Pharm 2018;44:144-57. [PMID: 28956451 DOI: 10.1080/03639045.2017.1386204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
113 Joseph S, Bunjes H. Solid Lipid Nanoparticles for Drug Delivery. In: Douroumis D, Fahr A, editors. Drug Delivery Strategies for Poorly Water-Soluble Drugs. Oxford: John Wiley & Sons Ltd; 2013. pp. 103-49. [DOI: 10.1002/9781118444726.ch4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Fang YP, Chuang CH, Wu PC, Huang YB, Tzeng CC, Chen YL, Liu YT, Tsai YH, Tsai MJ. Amsacrine analog-loaded solid lipid nanoparticle to resolve insolubility for injection delivery: characterization and pharmacokinetics. Drug Des Devel Ther 2016;10:1019-28. [PMID: 27019595 DOI: 10.2147/DDDT.S97161] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
115 Fonseca-Santos B, Gremião MP, Chorilli M. Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease. Int J Nanomedicine 2015;10:4981-5003. [PMID: 26345528 DOI: 10.2147/IJN.S87148] [Cited by in Crossref: 115] [Cited by in F6Publishing: 41] [Article Influence: 16.4] [Reference Citation Analysis]
116 Sharma M, Sharma R, Jain DK. Nanotechnology Based Approaches for Enhancing Oral Bioavailability of Poorly Water Soluble Antihypertensive Drugs. Scientifica (Cairo) 2016;2016:8525679. [PMID: 27239378 DOI: 10.1155/2016/8525679] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
117 Raposo SC, Simões SD, Almeida AJ, Ribeiro HM. Advanced systems for glucocorticoids' dermal delivery. Expert Opinion on Drug Delivery 2013;10:857-77. [DOI: 10.1517/17425247.2013.778824] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
118 Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target 2012;20:813-30. [PMID: 22931500 DOI: 10.3109/1061186X.2012.716845] [Cited by in Crossref: 203] [Cited by in F6Publishing: 40] [Article Influence: 20.3] [Reference Citation Analysis]
119 Silki, Sinha VR. Enhancement of In Vivo Efficacy and Oral Bioavailability of Aripiprazole with Solid Lipid Nanoparticles. AAPS PharmSciTech 2018;19:1264-73. [PMID: 29313261 DOI: 10.1208/s12249-017-0944-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]